Scarica l'app Stockscreener
2.53
1.56%
-0.04
Precedente Chiudi:
$2.57
Aprire:
$2.63
Volume 24 ore:
95,402
Relative Volume:
0.20
Capitalizzazione di mercato:
$11.21M
Reddito:
$20,000
Utile/perdita netta:
$-11.06M
Rapporto P/E:
-0.8893
EPS:
-2.8449
Flusso di cassa netto:
$-10.53M
1 W Prestazione:
-2.69%
1M Prestazione:
+0.80%
6M Prestazione:
+20.48%
1 anno Prestazione:
-16.23%
Intervallo 1D:
$2.53
$2.71
Intervallo di 1 settimana:
$2.45
$2.71
Portata 52W:
$1.7645
$3.29
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Nome
Kiora Pharmaceuticals Inc
Settore
Industria
Telefono
858-224-9600
Indirizzo
169 SAXONY RD., ENCINITAS
Compare KPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.53 | 11.21M | 20,000 | -11.06M | -10.53M | -2.8449 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kiora Pharmaceuticals Inc Borsa (KPRX) Ultime notizie
KPRX SEC FilingsKIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora Pharmaceuticals (KPRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Kiora Pharmaceuticals’ KIO-300 Shows Significant Seizure Suppression in Preclinical Epilepsy Model, Revealing Potential Beyond Ophthalmology 1 – Minichart - Minichart
Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kiora Pharmaceuticals (NASDAQ: KPRX) reports KIO-300 epilepsy model data - Stock Titan
Kiora's KIO-300 cut epileptiform activity in epilepsy model - Stock Titan
Kiora Pharmaceuticals Inc (KPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Institutional Confidence - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kiora Pharmaceuticals (NASDAQ: KPRX) director receives stock options for 25,000 shares - Stock Titan
Kiora Pharmaceuticals (KPRX) director receives 25,000 stock options grant - Stock Titan
Director at Kiora (KPRX) receives 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director granted 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director awarded 25,000 stock options - Stock Titan
Kiora (KPRX) director Praveen Tyle receives stock options for 40,000 shares - Stock Titan
Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan - TipRanks
Kiora Pharmaceuticals (NASDAQ: KPRX) OKs 1.5M-share equity plan boost and re-elects directors - Stock Titan
Kiora Pharmaceuticals (KPRX) Slips 4.9% as Stock Tests Key Support LevelsAD Line Divergence - newsline.com
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
KPRXKiora Pharmaceuticals Inc. stock news, filings & ratings - Quantisnow
Kiora Pharmaceuticals (KPRX) registers 11.8M shares including warrants - Stock Titan
Kiora Pharmaceuticals (KPRX) Holds Steady Near Support as Biotech Sector Faces HeadwindsTrading Ideas - The Legal Advocate
[EFFECT] KIORA PHARMACEUTICALS INC SEC Filing - Stock Titan
Kiora Pharmaceuticals (KPRX) Rallies 5.5%: Key Levels to Watch After Recent UptickStock Buy Zone - newsline.com
Kiora Pharmaceuticals (KPRX) Slips 4.5% as Stock Tests Key Support LevelDealer Gamma - The Legal Advocate
Kiora Pharmaceuticals Q1 2026 Earnings: EPS Beat Masks Continued Pre-Revenue Status as Stock SlipsAnalyst Drop Coverage - Newser
Kiora Pharmaceuticals (NASDAQ: KPRX) registers 11.8M resale shares - Stock Titan
Nantahala reports 9.99% stake in Kiora Pharmaceuticals (KPRX) - Stock Titan
Alyeska files 13G for Kiora (NASDAQ: KPRX) reporting 9.99% stake - Stock Titan
Nantahala holds 148,736 shares in Kiora Pharmaceuticals (KPRX) as 3.388% stake - Stock Titan
TradingKey - TradingKey
Number of shareholders of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
EDGAR Filing Documents for 0001372514-23-000110 - SEC.gov
Kiora (NASDAQ: KPRX) details Q1 2026 results and cash runway to 2028 - Stock Titan
Kiora Pharmaceuticals (NASDAQ: KPRX) reports Q1 loss but sees cash runway into late 2028 - Stock Titan
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update - TMX Newsfile
Is Kiora Pharmaceuticals (KPRX) stock hiding in plain sight? (Risk Aversion) 2026-05-07Take Profit Levels - newser.com
Kiora Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
[ARS] KIORA PHARMACEUTICALS INC SEC Filing - Stock Titan
KPRX Kiora Pharmaceuticals reports far wider Q4 2025 loss than estimates, shares hold flat in today’s trading. - newser.com
Kiora Pharmaceuticals (NASDAQ: KPRX) details 2026 director, pay and equity plan votes - Stock Titan
KPHMW SEC FilingsKiora Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora Pharmaceuticals (KPRX) Industry Outlook | Q4 2025: Earnings UnderperformRevision Downgrade - Cổng thông tin điện tử tỉnh Lào Cai
KPRX Kiora Pharmaceuticals posts far wider Q4 2025 loss than estimates, shares dip nearly 2 percent today.Cycle Outlook - Cổng thông tin điện tử tỉnh Tây Ninh
Eric J. Daniels to Resign as Kiora Chief Development Officer Effective April 17, 2026 - TradingView
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway - TMX Newsfile
Perceptive Fund (RLAY) reports 9.99% ownership — 438,471 shares - Stock Titan
Kiora Pharmaceuticals Inc Azioni (KPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):